The limited benefit of "product-by-process" claim

Hum Vaccin Immunother. 2016 Oct 2;12(10):2685-2687. doi: 10.1080/21645515.2016.1185211. Epub 2016 Jul 21.

Abstract

A product-by-process claim was initially developed when the invention could not otherwise be adequately defined. In the US, a patent applicant can use a product-by-process claim for a new product, no matter whether the product can also be defined by using structure features. However, the applicant mainly bears the burden to establish the novelty between the claimed product and the prior art product. Moreover, in terms of infringement, the very recent CAFC cases indicate that the product must be made by a process recited in the claim to infringe a product-by-process claim. Thus, an assignee almost can not take advantage from product-by-process claims during the patent enforcement by comparing with process claims. From the points of the burden during patent prosecution and confined scope in determining infringement, the benefit of using a product-by-process claim would be very limited.

Keywords: claim; development; infringement; patent; patentability; product-by-process; viral.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products / pharmacology*
  • Biotechnology
  • Humans
  • Patents as Topic*
  • United States

Substances

  • Biological Products